- Home
- BTAI vs BREA Comparison
BTAI vs BREA Comparison
Compare BTAI & BREA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BTAI
- BREA
- Stock Information
- Founded
- BTAI 2017
- BREA 2022
- Country
- BTAI United States
- BREA Ireland
- Employees
- BTAI N/A
- BREA N/A
- Industry
- BTAI Biotechnology: Pharmaceutical Preparations
- BREA Services-Misc. Amusement & Recreation
- Sector
- BTAI Health Care
- BREA Consumer Discretionary
- Exchange
- BTAI Nasdaq
- BREA Nasdaq
- Market Cap
- BTAI 8.4M
- BREA 9.4M
- IPO Year
- BTAI 2018
- BREA 2023
- Fundamental
- Price
- BTAI $1.84
- BREA $0.72
- Analyst Decision
- BTAI Buy
- BREA
- Analyst Count
- BTAI 5
- BREA 0
- Target Price
- BTAI $42.60
- BREA N/A
- AVG Volume (30 Days)
- BTAI 436.1K
- BREA 87.8K
- Earning Date
- BTAI 08-05-2025
- BREA 01-03-2025
- Dividend Yield
- BTAI N/A
- BREA N/A
- EPS Growth
- BTAI N/A
- BREA N/A
- EPS
- BTAI N/A
- BREA N/A
- Revenue
- BTAI $1,852,000.00
- BREA $2,988,009.00
- Revenue This Year
- BTAI $5.03
- BREA N/A
- Revenue Next Year
- BTAI $291.01
- BREA N/A
- P/E Ratio
- BTAI N/A
- BREA N/A
- Revenue Growth
- BTAI 5.47
- BREA 151.51
- 52 Week Low
- BTAI $1.17
- BREA $0.50
- 52 Week High
- BTAI $25.92
- BREA $1.95
- Technical
- Relative Strength Index (RSI)
- BTAI 64.53
- BREA 57.96
- Support Level
- BTAI $1.17
- BREA $0.66
- Resistance Level
- BTAI $1.48
- BREA $0.72
- Average True Range (ATR)
- BTAI 0.13
- BREA 0.04
- MACD
- BTAI 0.06
- BREA 0.00
- Stochastic Oscillator
- BTAI 100.00
- BREA 67.84
About BTAI BioXcel Therapeutics Inc.
BioXcel Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is focused on drug development utilizing novel artificial intelligence (AI) to identify the next wave of medicines across neuroscience and immuno-oncology. The pipeline products of the company are BXCL501 and BXCL701. The company's commercial product, IGALMI (developed as BXCL501) is a proprietary, sublingual film formulation of dexmedetomidine approved by the FDA for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults.
About BREA Brera Holdings PLC
Brera Holdings PLC focused on expanding social impact football by developing a international portfolio of emerging football clubs with increased opportunities to earn tournament prizes, gain sponsorships, and provide other professional football and related consulting services.